Galectin Therapeutics (GALT) Earnings Date, Estimates & Call Transcripts $2.82 +0.06 (+2.18%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Galectin Therapeutics Latest Earnings SummaryLatest Earnings DateAug. 13EstimatedActual EPS (Aug. 13) -$0.20 Missed By -$0.04 Consensus EPS (Aug. 13) -$0.16 Galectin Therapeutics issued Q2 2024 earnings on August 13, 2024, reporting an EPS of -$0.20, which missed the consensus estimate of -$0.16 by $0.04. With a trailing EPS of -$0.73, Galectin Therapeutics' earnings are expected to decrease next year, from ($0.73) to ($1.65) per share. Earnings Press Release Get Galectin Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataGALT Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GALT Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Galectin Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$0.16-$0.16-$0.16Q2 20241-$0.16-$0.16-$0.16Q3 20241-$0.17-$0.17-$0.17Q4 20241-$0.17-$0.17-$0.17FY 20244-$0.66-$0.66-$0.66Q1 20251-$0.24-$0.24-$0.24Q2 20251-$0.27-$0.27-$0.27Q3 20251-$0.63-$0.63-$0.63Q4 20251-$0.53-$0.53-$0.53FY 20254($1.67)($1.67)($1.67) Galectin Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks8/13/2024--$0.16-$0.20 -$0.04-$0.20-- 5/15/2024Q1 2024-$0.16-$0.19 -$0.03-$0.19-- 3/29/2024Q4 2023--$0.16 -$0.16-$0.16-- 11/13/2023Q3 2023-$0.16-$0.24 -$0.08-$0.24-- 8/14/2023Q2 2023-$0.21-$0.15+$0.06-$0.15-- 5/15/2023Q1 2023-$0.21-$0.19+$0.02-$0.19-- Get the Latest News and Ratings for GALT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/30/2023Q4 2022-$0.17-$0.18 -$0.01-$0.18-- Galectin Therapeutics Earnings - Frequently Asked Questions When did Galectin Therapeutics announce their last quarterly earnings? Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earning data on Tuesday, August 13, 2024. Learn more on GALT's earnings history. Did Galectin Therapeutics beat their earnings estimates last quarter? In the previous quarter, Galectin Therapeutics (NASDAQ:GALT) missed the analysts' consensus estimate of ($0.16) by $0.04 with a reported earnings per share (EPS) of ($0.20). Learn more on analysts' earnings estimate vs. GALT's actual earnings. How much profit does Galectin Therapeutics generate each year? Galectin Therapeutics (NASDAQ:GALT) has a recorded net income of -$41.07 million. GALT has generated -$0.73 earnings per share over the last four quarters. What is Galectin Therapeutics's EPS forecast for next year? Galectin Therapeutics's earnings are expected to decrease from ($0.79) per share to ($1.68) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies LUMO Earnings CRMD Earnings TRDA Earnings ABUS Earnings DNTH Earnings TECX Earnings PHAT Earnings EXAI Earnings ORIC Earnings ANAB Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. This page (NASDAQ:GALT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galectin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
